- Report
- June 2025
- 235 Pages
Global
From €2146EUR$2,450USD£1,862GBP
- Report
- August 2025
- 125 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- January 2026
- 187 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2026
- 474 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 463 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- July 2025
- 350 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- January 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2024
- 119 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- April 2023
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- February 2022
- 602 Pages
Europe
From €7878EUR$8,995USD£6,838GBP
- Report
- November 2019
China
From €7002EUR$7,995USD£6,078GBP
- Book
- February 2023
North America
- Book
- June 2022
- 1100 Pages
Prostatitis is a condition that affects the prostate gland, a small organ located near the bladder in men. It is characterized by inflammation of the prostate, which can cause pain, difficulty urinating, and other symptoms. Healthcare services for prostatitis include diagnosis, treatment, and management of the condition. Diagnosis typically involves a physical exam, laboratory tests, and imaging studies. Treatment may include antibiotics, anti-inflammatory medications, and lifestyle modifications. Management of the condition may include lifestyle changes, such as diet and exercise, and regular follow-up visits with a healthcare provider.
Companies in the prostatitis market include Astellas Pharma, Inc., Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., and Sanofi S.A. Show Less Read more
